Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01740817 · ClinicalTrials.gov registry record · NA

A Study to Evaluate the Effect of Lipid Infusion on Toll Like Receptor 4 (TLR4) Signaling

A NA study of Obesity and Diabetes, sponsored by The University of Texas Health Science Center at San Antonio.

Completed
Registry status
NA
Development phase
12
Enrollment target
1
Study location

NCT01740817 is a NA study of Obesity and Diabetes that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 12 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01740817, a NA study of Obesity and Diabetes, has completed, sponsored by The University of Texas Health Science Center at San Antonio.

COMPLETED
Registry status
NA
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine whether a lipid infusion can up-regulate toll-like receptor 4 (TLR4) signaling in human subjects

Conditions Studied

Interventions

  • DRUG Saline
  • DRUG Intralipid 20%

Study Locations (1)

Texas

  • Audie L. Murphy VA Hospital - San Antonio

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2008-01
Est. Completion 2015-09
Phase NA

What the Registry Record Tells You About NCT01740817

The ClinicalTrials.gov registry entry for NCT01740817 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (99% lower). The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Saline is the first listed.

NCT01740817 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT01740817 about?

NCT01740817 is a clinical study titled "A Study to Evaluate the Effect of Lipid Infusion on Toll Like Receptor 4 (TLR4) Signaling". The purpose of this study is to determine whether a lipid infusion can up-regulate toll-like receptor 4 (TLR4) signaling in human subjects

What is the current status of trial NCT01740817?

This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2008-01. Estimated completion is 2015-09.

What conditions does trial NCT01740817 study?

This clinical trial studies the following conditions: Obesity, Diabetes.

What interventions are being tested in trial NCT01740817?

The interventions under investigation include: Saline (DRUG), Intralipid 20% (DRUG).

Who is sponsoring clinical trial NCT01740817?

This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01740817 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.